Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 8/20 | 0.65 |
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | RECQL | P46063 | 1/20 | 0.56 |
| ▸ | GID4 | Q8IVV7 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 2/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | HTR2B | P41595 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6229660 | 1.00 | PRCP (0.65) | PRCPGAARECQLGID4MAPT | |
| SCHEMBL5520356 | 0.80 | CA1 (0.58) | PRCPGID4MAPTHTR2CMEN1 | |
| SCHEMBL28277290 | 0.79 | PRCP (1.00) | PRCPGAARECQLGID4MEN1 | |
| SCHEMBL7214001 | 0.79 | PRCP (1.00) | PRCPGAARECQLGID4MEN1 | |
| SCHEMBL30973183 | 0.79 | PRCP (1.00) | PRCPGAARECQLGID4MEN1 | |
| SCHEMBL22728763 | 0.79 | PRCP (1.00) | PRCPGAARECQLGID4MEN1 | |
| SCHEMBL11713664 | 0.78 | KMT2A (0.73) | GAATSHRMEN1KMT2A | |
| SCHEMBL14677303 | 0.78 | PRCP (0.65) | PRCPGAARECQLGID4MAPT | |
| SCHEMBL6227645 | 0.78 | HTR2C (0.46) | PRCPGAARECQLGID4HTR2C | |
| SCHEMBL28801361 | 0.78 | PRCP (0.62) | PRCPGAARECQLGID4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4135698-A2 | SMALL MOLECULE ANTIVIRAL DRUG TREATMENT FOR HUMAN PAPILLOMAVIRUS INFECTIONS | The Trustees of Indiana University (US) | 2023-02-22 | — | — | EP | disclosed |
| US-20230047626-A1 | SMALL MOLECULE ANTIVIRAL DRUG TREATMENT FOR HUMAN PAPILLOMAVIRUS INFECTIONS | THE TRUSTEES OF INDIANA UNIVERSITY | 2023-02-16 | — | — | US | disclosed |
| US-20220142973-A1 | SMALL MOLECULE ANTIVIRAL DRUG TREATMENT FOR HUMAN PAPILLOMAVIRUS INFECTIONS | THE TRUSTEES OF INDIANA UNIVERSITY | 2022-05-12 | — | — | US | disclosed |
| WO-2021212010-A2 | SMALL MOLECULE ANTIVIRAL DRUG TREATMENT FOR HUMAN PAPILLOMAVIRUS INFECTIONS | THE TRUSTEES OF INDIANA UNIVERSITY (US) | 2021-10-21 | — | — | WO | disclosed |
| EP-1487798-A4 | SUBSTITUTED TETRAHYDROISOQUINOLINES AS C5A RECEPTOR MODULATORS | NEUROGEN CORP (US) | 2005-07-13 | — | — | EP | disclosed |
| US-6916830-B2 | Substituted tetrahydroisoquinolines as C5a receptor modulators | NEUROGEN CORPORATION (US) | 2005-07-12 | — | — | US | disclosed |
| EP-1487798-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINES AS C5A RECEPTOR MODULATORS | Neurogen Corporation (US) | 2004-12-22 | — | — | EP | disclosed |
| US-20040204446-A1 | Nitrogen compounds such as N-(2-Fluoro-benzyl)-N-indan-2-yl-2-(3-methyl-2-o-tolyl-piperidin-1-yl) -acetamide, administered for prophylaxis arthritis, psoriasis, cardiovascular disorders, reperfusion injury or respiratory system disorders | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2004-10-14 | — | — | US | disclosed |
| US-6777422-B2 | FOR TREATING A VARIETY OF INFLAMMATORY AND IMMUNE SYSTEM DISORDERS | NEUROGEN CORP. | 2004-08-17 | — | — | US | disclosed |
| US-20040006069-A1 | Substituted tetrahydroisoquinolines as C5a receptor modulators | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2004-01-08 | — | — | US | disclosed |
| WO-2003082828-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINES AS C5A RECEPTOR MODULATORS | NEUROGEN CORPORATION (US) | 2003-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230047626-A1 | SMALL MOLECULE ANTIVIRAL DRUG TREATMENT FOR HUMAN PAPILLOMAVIRUS INFECTIONS | TP53, EIF2AK2, POLI | PRCP 1119/4885GAA 2301/4885RECQL 223/4885 |
| US-20040006069-A1 | Substituted tetrahydroisoquinolines as C5a receptor modulators | C5AR1, C3AR1, C5AR2 | PRCP 600/4885GAA 4731/4885RECQL 1631/4885 |
| US-20220142973-A1 | SMALL MOLECULE ANTIVIRAL DRUG TREATMENT FOR HUMAN PAPILLOMAVIRUS INFECTIONS | TP53, EIF2AK2, POLI | PRCP 1119/4885GAA 2301/4885RECQL 223/4885 |
| US-20040204446-A1 | Nitrogen compounds such as N-(2-Fluoro-benzyl)-N-indan-2-yl-2-(3-methyl-2-o-tolyl-piperidin-1-yl) -acetamide, administered for prophylaxis arthritis, psoriasis, cardiovascular disorders, reperfusion injury or respiratory system disorders | C5AR1, C3AR1, C5AR2 | PRCP 2373/4885GAA 4746/4885RECQL 3453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.